Tenofovir 1% Vaginal Gel for Prevention of HIV-1 Infection in Women in South Africa (FACTS-001): a Phase 3, Randomised, Double-Blind, Placebo-Controlled Trial
The primary results of FACTS 001, a randomized, placebo-controlled trial conducted in South Africa to evaluate the safety and efficacy of 1% tenofovir vaginal gel, are presented in an article in The Lancet Infectious Diseases.
External Links:
Year:
2018
Organization:
Wits Reproductive Health and HIV Institute
Languages:
English
Author(s):
Delany-Moretlwe S, Lombard C, Baron D, Bekker LG, et al.